Patents by Inventor Piotr Masiakowski

Piotr Masiakowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA encoding human ciliary neurotrophic factor and method for producing the protein encoded thereby
    Patent number: 6602687
    Abstract: The present invention relates to nucleic acid sequences encoding ciliary neurotrophic factor (CNTF) and to the proteins, peptides, and derivatives produced therefrom. In various embodiments of the invention, the nucleic acid sequences, proteins, and peptides of the invention may be used in the treatment of a variety of neurological diseases and disorders, including Alzheimer's disease. In a specific embodiment of the invention, CNTF may be used to support the growth of spinal cord neurons, thereby providing a method of treating spinal cord damage caused by trauma infarction, infection, nutritional deficiency or toxic agents. The present invention also relates to a novel method for producing substantilly pure CNTF. The invention also relates to pharmaceutical compositions comprising effective amounts of CNTF gene products which may be used in the diagnosis and treatment of a variety of neurologial diseases and disorders.
    Type: Grant
    Filed: May 8, 1992
    Date of Patent: August 5, 2003
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Michael Sendtner, Kurt Stockli-Rippstein, Friedrich Lottspeich, Yoshihiro Arakawa, Patrick Desmond Carroll, Rudolf Georg Gotz, Georg W. Kreutzberg, Dan B. Lindholm, Piotr Masiakowski, Vivien Wong, Nancy Ip, Mark E. Furth, Nikos Panayotatos, Hans Thoenen
  • Ehk and Ror tyrosine kinases
    Patent number: 5843749
    Abstract: The present invention provides for novel receptor tyrosine kinases known as Ror-1, Ror-2, Ehk-1 and Ehk-2. The invention also provides for assay systems that may be used to detect and/or measure neurotrophin activity or to identify agents that exhibit neurotrophin-like activity. It is based, at least in part, on the discovery that the trkB proto-oncogene encodes a tyrosine kinase receptor that may serve as a functional binding protein for BDNF and NT-3. The present invention also provides for diagnostic and therapeutic methods based on the interaction between BDNF and/or NT-3 and trkB.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 1, 1998
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Peter C. Maisonpierre, Piotr Masiakowski, George D. Yancopoulos